Free Trial
NASDAQ:LENZ

LENZ Therapeutics (LENZ) Stock Price, News & Analysis

LENZ Therapeutics logo
$38.63 +0.43 (+1.13%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$38.62 -0.01 (-0.03%)
As of 08/29/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About LENZ Therapeutics Stock (NASDAQ:LENZ)

Key Stats

Today's Range
$37.84
$38.87
50-Day Range
$29.31
$40.91
52-Week Range
$16.53
$41.70
Volume
222,755 shs
Average Volume
788,388 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.60
Consensus Rating
Buy

Company Overview

LENZ Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

LENZ MarketRank™: 

LENZ Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 786th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about LENZ Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LENZ Therapeutics is -20.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LENZ Therapeutics is -20.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LENZ Therapeutics has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENZ Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.64% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving.
  • Dividend Yield

    LENZ Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LENZ Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.64% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving.
  • News Sentiment

    LENZ Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    13 people have searched for LENZ on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of LENZ Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENZ Therapeutics' insider trading history.
Receive LENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LENZ Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
See More Headlines

LENZ Stock Analysis - Frequently Asked Questions

LENZ Therapeutics' stock was trading at $28.87 at the start of the year. Since then, LENZ shares have increased by 33.8% and is now trading at $38.63.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) posted its earnings results on Wednesday, July, 30th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.05. The business earned $5 million during the quarter, compared to analyst estimates of $5 million.

LENZ Therapeutics' top institutional shareholders include Adage Capital Partners GP L.L.C. (3.94%), Geode Capital Management LLC (1.46%), Saturn V Capital Management LP (1.20%) and Invesco Ltd. (0.94%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum.
View institutional ownership trends
.

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2025
Today
8/31/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LENZ
Previous Symbol
NASDAQ:LENZ
CIK
1815776
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$60.00
Low Price Target
$40.00
Potential Upside/Downside
+28.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.77 million
Net Margins
N/A
Pretax Margin
-1,037.94%
Return on Equity
-25.63%
Return on Assets
-24.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.54
Quick Ratio
20.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.24 per share
Price / Book
5.34

Miscellaneous

Outstanding Shares
28,520,000
Free Float
26,554,000
Market Cap
$1.10 billion
Optionable
N/A
Beta
0.42

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:LENZ) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners